We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+7.3%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$164M
AUM Growth
+$4.83M
Cap. Flow
-$759K
Cap. Flow %
-0.46%
Top 10 Hldgs %
85.32%
Holding
58
New
4
Increased
8
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$1.16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.12M
3
DERM
Dermira, Inc.
DERM
+$1.08M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$918K
5
BIIB icon
Biogen
BIIB
+$577K

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$5.79M
2
IFRX icon
InflaRx
IFRX
+$605K
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$387K
4
CELG
Celgene Corp
CELG
+$128K
5
ATRA icon
Atara Biotherapeutics
ATRA
+$113K

Sector Composition

Rank Sector Weight
1 Healthcare 96.53%
2 Energy 1.97%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.05%
5 Materials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
26
DELISTED
Soleno Therapeutics
SLNO
$674K 0.41%
16,040
– –
ARVN icon
27
Arvinas
ARVN
$517M
$660K 0.4%
30,000
– –
ICPT
28
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$660K 0.4%
8,300
– –
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
$585K 0.36%
3,800
– –
CORT icon
30
Corcept Therapeutics
CORT
$9.83B
$558K 0.34%
50,000
– –
MYGN icon
31
Myriad Genetics
MYGN
$559M
$556K 0.34%
20,000
– –
LXRX icon
32
Lexicon Pharmaceuticals
LXRX
$1.03B
$503K 0.31%
80,000
– –
XNCR icon
33
Xencor
XNCR
$1.39B
$503K 0.31%
12,300
– –
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$474K 0.29%
38,000
– –
KPTI icon
35
Karyopharm Therapeutics
KPTI
$169M
$419K 0.25%
4,667
– –
ATRA icon
36
Atara Biotherapeutics
ATRA
$74.7M
$402K 0.24%
800
-160
-17% -$113K
IMGN
37
DELISTED
Immunogen Inc
IMGN
$391K 0.24%
180,000
+90,000
+100% +$213K
NKTR icon
38
Nektar Therapeutics
NKTR
$2.19B
$338K 0.21%
633
– –
CLR
39
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$337K 0.21%
8,000
– –
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.3B
$267K 0.16%
+10,000
New +$255K
SIEN
41
DELISTED
Sientra, Inc.
SIEN
$246K 0.15%
4,000
– –
OVV icon
42
Ovintiv
OVV
$16.2B
$244K 0.15%
9,500
– –
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$203K 0.12%
+8,000
New +$163K
EQT icon
44
EQT Corp
EQT
$30.7B
$179K 0.11%
11,300
– –
TGTX icon
45
TG Therapeutics
TGTX
$8.26B
$130K 0.08%
15,000
– –
CFRX
46
DELISTED
ContraFect Corporation
CFRX
$123K 0.07%
300
– –
MREO
47
Mereo BioPharma
MREO
$48.7M
$120K 0.07%
+47,570
New +$208K
YTEN
48
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$120K 0.07%
129
– –
CYTK icon
49
Cytokinetics
CYTK
$10.7B
$113K 0.07%
10,000
– –
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.32B
$76K 0.05%
+20,000
New +$120K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Birchview Capital held 58 positions worth $164M, up 3% from $160M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Birchview Capital's Q2 2019 filing shows 4 new, 8 increased, 3 reduced and 4 closed positions. Its largest new stake was Acadia Pharmaceuticals: 10,000 shares worth $267K. The largest sale was Clementia Pharmaceuticals Inc., an estimated $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2019 buy was Acadia Pharmaceuticals: 10,000 shares worth $267K.
  • Birchview Capital added most to Vermillion, Inc. in Q2 2019, an estimated $1.16M increase.
  • Birchview Capital's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $128K.
  • Birchview Capital fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $5.79M.
  • Birchview Capital's ten largest holdings make up 85% of its $164M portfolio in Q2 2019.
  • Birchview Capital opened 4 new positions and closed 4 in Q2 2019.
  • Birchview Capital's portfolio value rose 3% quarter-over-quarter to $164M.

Based on Birchview Capital's 13F filing for Q2 2019, filed 6 Aug 2019.